Lataa...
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering it an at...
Tallennettuna:
| Julkaisussa: | J Immunother Cancer |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5987486/ https://ncbi.nlm.nih.gov/pubmed/29866197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0361-7 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|